Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs IONQ Inc (IONQ) Price & Performance

Abbott LaboratoriesTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs IONQ Inc — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while IONQ Inc trades at $44.96 (market cap $17.60B). The key difference: Abbott Laboratories is far larger — about 10.7× IONQ Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.

ABTIONQ
Market Cap
$187.95B$17.60B
Sector
HealthTechnology
52-Week High
$136.62$82.09
52-Week Low
$82.57$26.59
Enterprise Value
$214.96B$15.53B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

IONQ Inc

IONQ trades at $45.20, up 6.28% today, with a bullish technical signal from moving averages and strong resistance near $46. The company reported Q2 2026 revenue growth of 287% to $80.1 million, though it missed EPS estimates. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism on quantum computing leadership.

Outlook is growth-driven but high-risk; revenue is projected to double in 2026, yet net losses exceed $1.4 billion. Key risks include profitability timeline, cash burn, and competitive pressures. Upside hinges on execution of its quantum roadmap and defense contracts, but volatility persists.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About IONQ Inc

IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.

Read more on IONQ